

**CENTER FOR DRUG EVALUATION AND RESEARCH**

**APPLICATION NUMBER: NDA 20912/S001**

**CHEMISTRY REVIEW(S)**

FEB 17 1999

<b>CHEMIST'S REVIEW</b>		<b>1. ORGANIZATION</b> HFD-110	<b>2. NDA Number</b> 20-912, [REDACTED]
<b>3. Name and Address of Applicant (City &amp; State)</b> Merck Research Laboratories Sumneytown Pike, P.O. Box-4, BLA-20 West Point, PA 19486		<b>4. Supplement(s) Number(s) + Date(s)</b> SLR-001 10/16/98 SLR-001BC 02/12/99	
<b>5. Drug Name</b> AGGRASTAT Injection & Injection Premixed	<b>6. Nonproprietary Name</b> Tirofiban hydrochloride	<b>8. Amendments &amp; Other (reports, etc) - Dates</b>	
<b>7. Supplement Provides For:</b> Changes in labeling.			
<b>9. Pharmacological Category</b> Non-peptide antagonist of the platelet glycoprotein IIb/IIIa receptor	<b>10. How Dispensed</b> <input checked="" type="checkbox"/> Rx <input type="checkbox"/> OTC	<b>11. Related IND(s)/NDA(s)/DMF(s)</b>	
<b>12. Dosage Form(s)</b> Injection & Injection premixed (intravenous)	<b>13. Potency (ies)</b> 0.25 mg/mL & 0.05 mg/mL		
<b>14. Chemical Name and Structure</b> N-(butylsulfonyl)-O-[4-(4-piperidiny)butyl]-L-tyrosine monohydrochloride monohydrate		<b>15. Records/Reports Current</b> <input type="checkbox"/> Yes <input type="checkbox"/> No Reviewed <input type="checkbox"/> Yes <input type="checkbox"/> No	
<b>16. Comments:</b> The circular has been revised under CLINICAL PHARMACOLOGY, Clinical Trials and <u>DOSAGE AND ADMINISTRATION</u> .  Under Directions for use section, for accuracy it is indicated that Premixed is supplied as 500 mL of 0.9% sodium chloride containing 50 ug/mL tirofiban. Originally erroneously it was shown as 50 ug/mL tirofiban HCL.  Also the statement " AGGRASTAT may be administered in the same intravenous line as dopamine, lidocaine, and potassium chloride, and PEPCID (famotidine) Injection." is added. Firm has provided the supportive data in attachments 2-5, on the compatibility studies of indicated drugs with AGGRASAT Injection Firm has also provided as per our telephone request, description of the HPLC methods used and sample chromatograms (amendment of 02/12/99 data in attachments 5). Also clarified the chemical structure and provided the references to the stability studies data that justifies to eliminate the precaution to discard unused solution after 24 hours. Firm has clarified why the intravenous line compatibility studies were upto 4 hours duration as maximum contact time of the solutions in the infusion is between 1 minute and 1 hour.  Satisfactory for DESCRIPTION and HOW SUPPLIED sections.			
<b>17. Conclusions and Recommendations:</b> Satisfactory, in respect to DESCRIPTION and HOW SUPPLIED sections.			
<b>18. REVIEWER</b>			
<b>Name</b> JV Advani	<b>Signature</b> [Signature]	<b>Date Completed</b> 02/16/99	
<b>Distribution:</b> <input checked="" type="checkbox"/> Original Jacket <input checked="" type="checkbox"/> Reviewer <input checked="" type="checkbox"/> Division File <input checked="" type="checkbox"/> CSO			

20913S01.SUP

15  
2-17-99